Jason Laufer
RDD Pharma, a clinical stage company with programs in:
1. Fecal incontinence (Phase 2a)
2. Chronic anal fissure (Phase 3 ready).
3. Pruritus Ani - preclinical development
4. Radiation Colitis - animal studies
- All rograms utilize a 505(b)2 strategy .
- Anal Fissure IP goes out to 2030.
1. Fecal incontinence (Phase 2a)
2. Chronic anal fissure (Phase 3 ready).
3. Pruritus Ani - preclinical development
4. Radiation Colitis - animal studies
- All rograms utilize a 505(b)2 strategy .
- Anal Fissure IP goes out to 2030.